Liquid biopsies are revolutionizing modern oncology by offering a noninvasive method for tumor profiling and longitudinal monitoring. However, the reliability of these assays depends heavily on liquid biopsy pre-analytical optimization. While clinicians frequently rely on cell-free DNA (cfDNA), extracellular vesicle-derived DNA (evDNA) is emerging as a critical analyte. Understanding how storage and processing affect these molecules is essential for accurate clinical results.

Standardizing Liquid Biopsy Pre-Analytical Optimization

Recent research evaluated four critical variables: processing delay, storage temperature, tube type, and plasma input volume. Findings indicate that cfDNA concentrations start increasing after 24 hours at room temperature. In contrast, evDNA remains stable for up to 48 hours. Retrospective analyses suggest even tighter windows, with changes occurring as early as 6 hours for cfDNA. Furthermore, short-term refrigeration at 4°C preserves DNA quality significantly better than immediate -80°C freezing of whole plasma. Consequently, maintaining a cold chain is vital for sample integrity.

Regarding collection tubes, Acid Citrate Dextrose (ACD) and KEDTA tubes show comparable performance if processed promptly. Interestingly, higher plasma volumes specifically benefit evDNA detection rather than cfDNA. Ultimately, evDNA demonstrates superior resilience under suboptimal conditions. This resilience makes it a promising biomarker for settings where immediate processing is unavailable. Therefore, laboratories must choose their analytes based on their specific logistics and clinical goals.

Clinical Takeaways for Practitioners

To ensure high-quality results, laboratories must implement standardized workflows. Prompt processing is the most effective way to prevent genomic DNA contamination from cell lysis. Specifically, refrigeration should be the preferred short-term storage method for whole blood samples. As liquid biopsy technology matures, these optimizations will become mandatory for precision oncology in India and globally. Furthermore, clinicians should communicate clearly with pathology labs regarding the timing of blood draws.

What is the primary benefit of evDNA over cfDNA?

Extracellular vesicle-derived DNA (evDNA) is often more stable because the lipid bilayer of the vesicle protects the genetic material from enzymatic degradation and external stress.

Which tube type is best for liquid biopsy?

Under prompt processing conditions, both KEDTA and ACD tubes provide reliable results for mutation detection without significant differences in performance.

How does temperature affect sample stability?

Short-term refrigeration at 4°C is superior for preserving DNA integrity compared to freezing plasma at -80°C before the extraction process is completed.

Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or to replace the professional judgment of a healthcare provider. Refer to the latest local and national guidelines for clinical practice.

References

Dohmen J et al. Pre-analytical optimization of cell-free DNA and extracellular vesicle-derived DNA for mutation detection in liquid biopsies. Mol Oncol. 2026 Feb 22. doi: 10.1002/1878-0261.70222. PMID: 41725045.

Thierry AR et al. Clinical utility of the liquid biopsy in oncology: Journal of Clinical Medicine. 2021;10(14):3152.

Elzanowska J et al. Extracellular Vesicle-Derived DNA vs. CfDNA as a Biomarker for the Detection of Colon Cancer. PMC. 2021 Jul 29.